Korea's SK pharmteco invests more than $200 M to expand small molecule and peptide capacity in US

image credit- shutterstock

SK pharmteco, a subsidiary of SK Inc., the strategic investment company for SK Group, South Korea’s second-largest conglomerate, has announced a comprehensive five-year, more than $200 million investment plan to expand and upgrade its US development and manufacturing infrastructure across small molecules and peptides.

This continues SK pharmteco’s global growth strategy, complementing the company's recent $6 million investment in its California facility to boost peptide development, the opening of two advanced manufacturing facilities at its Ireland campus to scale up the site’s capability to deliver both large-scale commercial small molecules and ultra-high-potency active pharmaceutical ingredients (HPAPIs), and its $260 million capacity expansion in South Korea to expand global small molecule and peptide production.

As part of this new domestic plan, SK pharmteco will make targeted investments across key technology platforms, including:

• State-of-the-Art Development Labs: Launching new, fully operational development laboratories to accelerate early- through late-stage development for small molecules and peptides
• Advanced Peptide Purification: Expanding peptide manufacturing with new GMP kilo-scale capacity (scheduled to be operational in late 2026) alongside advanced liquid chromatography capabilities
• Expanded & Upgraded Manufacturing: Constructing new manufacturing suites and modernising existing GMP capacity to meet growing demand for small-molecule APIs
• Infrastructure & Sustainability: Investing heavily in utility upgrades, logistics and digital infrastructures, and green technology to ensure sustainable, high-efficiency operations

The multi-year investment is projected to create 100 long-term, high-skilled jobs in the US, significantly strengthening domestic capabilities in active pharmaceutical ingredient (API), peptide, and advanced therapy supply.